GNPX 3.18 Genprex, Inc.
| Range: | 0.281-14.8 | Vol Avg: | 537543 | Last Div: | 0 | Changes: | 0.07 |
| Beta: | -0.6 | Cap: | 0.00B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Thu Mar 29 2018 | Empoloyees: | 21 | ||
| CUSIP: | 372446104 | CIK: | 0001595248 | ISIN: | US3724462037 | Country: | US |
| CEO: | Mr. Ryan M. Confer M.S. | Website: | https://www.genprex.com | ||||
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow